Biovica International Ab Class B · OMXSTO:BIOVIC_B
Biovica International Ab Class B — Q3 2024 Earnings Presentation
31 slides from Biovica International Ab Class B's earnings presentation, Mar 14, 2024
Slide 1: Biovica International AB
©2023 Biovica International AB
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: Q3 Interim Report Presenters
Q3 Interim Report Presenters Anders Rylander CEO Warren Cresswell President Biovica Americas Henrik Winther SVP Business Development Anders Morén CFO 3 ©2023 Biovica International AB
Slide 4: Agenda
Agenda Biovica introduction Q3 Highlights US Update Pharma Services Financial Update Summary and Q&A ©2023 Biovica International AB – Proprietary and Confidential. ©2023 All rights reserved. Biovica International AB
Slide 5: Q&A Session
Q&A Session 5 ©2023 Biovica International AB
Slide 6: Biovica Introduction
Biovica Introduction ©2023 Biovica International AB
Slide 7: DiviTum TKa
DiviTum® TKa An early indicator of cancer treatment effectiveness + References: http://biovica.com/technology/publications/ DiviTum® TKa cell proliferation provides quicker evaluation of cancer treatment efficacy. ©2023 Biovica International AB
Slide 8: Validated by a wealth of scientific evidence
Validated by a wealth of scientific evidence 30+ published and peer-reviewed articles Cancer Area Patients Nr. of studies Strong evidence supporting the use of Breast Cancer 3,039 14 DiviTum® TKa as a clinical biomarker Gastrointestinal 713 4 of CDK4/6i response Malignant Melanoma 86 2 Collaboration
Slide 9: Strategically designed launch plan ensures growth
Strategically designed launch plan ensures growth ©2023 Biovica International AB
Slide 10: Q3 Highlights
Q3 Highlights 10 ©2023 Biovica International AB
Slide 11: Q3 2023/2024 Highlights
Q3 2023/2024 Highlights Significant events during the Q3 November-January • US • Biovica receives final pricing decision for DiviTum TKa test by Medicare effective January 1, 2024 • Biovica is licensed for the state of Maryland • DiviTum TKa in three posters at the world's largest breast cancer conf
Slide 12: Q3 2023/2024 Highlights
Q3 2023/2024 Highlights Significant events after the end of the period • US • Interventional DiviTum TKa trial launches at Washington University • Pharma Services • Biovica signs master service agreement for TKa testing with Tier1 pharma (1,7 MSEK) • Biovica signs master service agreement for TKa te
Slide 13: US Update
US Update 13 ©2023 Biovica International AB
Slide 14: Agenda
Agenda Sales & Contracting Performance Reimbursement Milestones Regulatory Progress Clinical Trial Activities Real World Patient Data Using DiviTum TKa ©2023 Biovica International AB
Slide 15: Sales and Contracting Performance
Sales and Contracting Performance Sales Performance Hospital Contracts DiviTum orders doubled in Q3 over Q2 Goal = 10 12 ordering institutions in Q3; 5 more than Q2 Executed = 3 93% of physicians have ordered multiple Pipeline = 14* DiviTum tests *Currently receiving orders from NCI / NCCN 47% of pa
Slide 16: Reimbursement Milestones
Reimbursement Milestones 1 Medicare 2 Private Insurance 3 Client Bill PLA Code was activated on Claims including Managed All claims are being paid at the Jan 1, 2024 @ $322/test Medicare are being paid contracted price Payments are being received Getting setup as a provider in This continues to be a
Slide 17: Certification, Credentialling, Accreditation & Licensing
Certification, Credentialling, Accreditation & Licensing DiviTum is available in 49 states and Washington DC Mar 2023 H2 2024 Feb 2023 Oct 2023 ©2023 Biovica International AB
Slide 18: Interventional Clinical Trial Activities & Indication Expansion
Interventional Clinical Trial Activities & Indication Expansion Current Indication Indication Expansion Clinical utility data development in MBC Adjuvant Breast Cancer Drug to Drug Interaction and Dose Reduction Retrospective TKa analysis from a CDK4/6 Inhibition in HR+ MBC CDK4/6i clinical trial 1,
Slide 19: Real World Patient Data Using DiviTum TKa
Real World Patient Data Using DiviTum TKa High TKa Triggered a Biopsy and Therapeutic Switch due to Discovery of Liver Metastasis Tolerability Issues A C Dose Reduction due to Tolerability Issues Low TKa Indicates Response to Therapy B D ©2023 Biovica International AB
Slide 20: Pharma Services Update
Pharma Services Update 20 ©2023 Biovica International AB
Slide 21: The Pharma Services & Collaboration Business
The Pharma Services & Collaboration Business - continues its strong progress with new agreements and increased sales 1. Service & Kit Sales 2. CDx Collaborations 3. CDx Product Sales TESA* CDx Development CDx product on the market MSA** Collaboration fee-for-services (Revenues depends on patient (Mu
Slide 22: Current Pharma/Biotech customers represent a significant CDx TAM
Current Pharma/Biotech customers represent a significant CDx TAM – and additional drugtypes are in our pipeline TKa- Number of Customers drug targets customer customers TIER-1 (>10 BUSD) 3 (+ 1 in discus.) CDKi’s (4/4) Typical CDx customer TIER-2 (1-10 BUSD) 2 CDKi’s (2/2) Developing new drugs for T
Slide 23: Financial Update
Financial Update 23 ©2023 Biovica International AB
Slide 24: YTD Net Sales by Quarter (KSEK)
YTD Net Sales by Quarter (KSEK) 6 000 6 000 5 391 5 000 5 000 4 000 4 000 3 000 3 000 2 432 2 000 2 000 1 000 1 000 - - Q1 Q2 Q3 Q4 2023/2024 Total 2022/2023 Total ©2023 Biovica International AB
Slide 25: YTD US IVD Sales by Quarter (KSEK)
YTD US IVD Sales by Quarter (KSEK) 400 365 350 300 250 Test distr. Revenue dist. Private insurance 34% 12% 200 Medicare 46% 38% Client bill 20% 50% 100% 100% 150 100 66 50 12 - Q1 Q2 Q3 Q4 ©2023 Biovica International AB
Slide 26: Cash Position by quarter (MSEK)
Cash Position by quarter (MSEK) 160,00 140,00 120,00 105,2 100,00 80,00 60,00 40,00 20,00 - Q1 Q2 Q3 Q4 Cash 2023/2024 Cash 2022/2023 ©2023 Biovica International AB
Slide 27: Net Operating Cash flow by Quarter (MSEK)
Net Operating Cash flow by Quarter (MSEK) Q4 22/23 Q1 23/24 Q2 23/24 Q3 23/24 10 Millions 5 -5 - 10 - 15 - 20 -22,8 - 25 - 30 -28,3 - 35 - 40 - 45 Operating Cash flow before change in Working Capital Change in Working Capital Net Operating Cashflow ©2023 Biovica International AB
Slide 28: Summary & QA
Summary & QA ©2023 28 Biovica International AB
Slide 29: Summary & Targets
Summary & Targets Progress made during Q3 Measures cell proliferation from a simple blood sample US: Growth in revenue, # patients being monitored, # DiviTum® TKa addresses an important clinical unmet need oncologists and institutions ordering. Pharma Services: New agreements – 11,4 MSEK order book.
Slide 30: Biovica International AB
30 ©2023 Biovica International AB
Slide 31: Biovica International AB
31 ©2023 Biovica International AB
Biovica International — Q3 2024 Earnings Presentation on 6ix